Eisai
Amir A. Tahami serves as the Head of Global Value & Access, Pricing and HEOR at Eisai US, focusing on market access strategies for neurology and oncology products. With extensive experience in shaping pricing and access frameworks, Amir has led initiatives for the US market access of Eisai’s Alzheimer’s portfolio and has a history of strategic leadership at companies like Bristol Myers Squibb and Merck. Additionally, Amir holds adjunct professorships at McGill University and NYU, emphasizing healthcare analytics and health economics. As an Associate Editor for the Journal of Alzheimer’s Disease, Amir contributes to advancing research in Alzheimer's and has a strong academic background with multiple advanced degrees from prestigious institutions.
This person is not in any teams
This person is not in any offices
Eisai
12 followers
Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The other segment consists of pharmaceutical raw materials, logistics services and business services businesses.